 Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancerJoseph Tintelnot (),
Yang Xu,
Till R. Lesker,
Martin Schönlein,
Leonie Konczalla,
Anastasios D. Giannou,
Penelope Pelczar,
Dominik Kylies,
Victor G. Puelles,
Agata A. Bielecka,
Manuela Peschka,
Filippo Cortesi,
Kristoffer Riecken,
Maximilian Jung,
Lena Amend,
Tobias S. Bröring,
Marija Trajkovic-Arsic,
Jens T. Siveke,
Thomas Renné,
Danmei Zhang,
Stefan Boeck,
Till Strowig,
Faik G. Uzunoglu,
Cenap Güngör,
Alexander Stein,
Jakob R. Izbicki,
Carsten Bokemeyer,
Marianne Sinn,
Alec C. Kimmelman,
Samuel Huber and
Nicola Gagliani ()
Nature, 2023, vol. 615, issue 7950, 168-174 Abstract: Abstract Pancreatic ductal adenocarcinoma (PDAC) is expected to be the second most deadly cancer by 2040, owing to the high incidence of metastatic disease and limited responses to treatment1,2. Less than half of all patients respond to the primary treatment for PDAC, chemotherapy3,4, and genetic alterations alone cannot explain this5. Diet is an environmental factor that can influence the response to therapies, but its role in PDAC is unclear. Here, using shotgun metagenomic sequencing and metabolomic screening, we show that the microbiota-derived tryptophan metabolite indole-3-acetic acid (3-IAA) is enriched in patients who respond to treatment. Faecal microbiota transplantation, short-term dietary manipulation of tryptophan and oral 3-IAA administration increase the efficacy of chemotherapy in humanized gnotobiotic mouse models of PDAC. Using a combination of loss- and gain-of-function experiments, we show that the efficacy of 3-IAA and chemotherapy is licensed by neutrophil-derived myeloperoxidase. Myeloperoxidase oxidizes 3-IAA, which in combination with chemotherapy induces a downregulation of the reactive oxygen species (ROS)-degrading enzymes glutathione peroxidase 3 and glutathione peroxidase 7. All of this results in the accumulation of ROS and the downregulation of autophagy in cancer cells, which compromises their metabolic fitness and, ultimately, their proliferation. In humans, we observed a significant correlation between the levels of 3-IAA and the efficacy of therapy in two independent PDAC cohorts. In summary, we identify a microbiota-derived metabolite that has clinical implications in the treatment of PDAC, and provide a motivation for considering nutritional interventions during the treatment of patients with cancer. Date: 2023 Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:615:y:2023:i:7950:d:10.1038_s41586-023-05728-y Ordering information: This journal article can be ordered from DOI: 10.1038/s41586-023-05728-y Access Statistics for this article Nature is currently edited by Magdalena Skipper More articles in Nature from Nature |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.